Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain.

Autor: Maciá-Martínez MÁ; Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain. mmacia@aemps.es., Castillo-Cano B; Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain., García-Poza P; Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain., Martín-Merino E; Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain.

Publikováno v: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Oct; Vol. 80 (10), pp. 1503-1514. Date of Electronic Publication: 2024 Jun 22.

Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.

Autor: Riefolo F; Teamit Institute, Partnerships, Barcelona Health Hub, Barcelona, Spain; VAccine Monitoring Collaboration for Europe, Brussels, Belgium., Castillo-Cano B; Spanish Agency of Medicines and Medical Devices-AEMPS, Madrid, Spain., Martín-Pérez M; Spanish Agency of Medicines and Medical Devices-AEMPS, Madrid, Spain., Messina D; Agenzia Regionale di Sanita' Toscana, Florence, Italy., Elbers R; Department of Data Science and Biostatistics, University Medical Center Utrecht, the Netherlands., Brink-Kwakkel D; Department of Data Science and Biostatistics, University Medical Center Utrecht, the Netherlands., Villalobos F; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain., Ingrasciotta Y; Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Garcia-Poza P; Spanish Agency of Medicines and Medical Devices-AEMPS, Madrid, Spain., Swart-Polinder K; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands., Souverein P; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands., Saiz LC; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Spain., Bissacco CA; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain., Leache L; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Spain., Tari M; Caserta Local Health Unit, Caserta, Italy., Crisafulli S; Department of Medicine, University of Verona, Verona, Italy., Grimaldi L; l'Assistance Publique-Hôpitaux de Paris (APHP), University Paris-Saclay, Paris, France., Vaz T; Department of Data Science and Biostatistics, University Medical Center Utrecht, the Netherlands., Gini R; VAccine Monitoring Collaboration for Europe, Brussels, Belgium; Agenzia Regionale di Sanita' Toscana, Florence, Italy., Klungel O; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands., Martín-Merino E; VAccine Monitoring Collaboration for Europe, Brussels, Belgium; Spanish Agency of Medicines and Medical Devices-AEMPS, Madrid, Spain. Electronic address: emartinm@aemps.es.

Publikováno v: Vaccine [Vaccine] 2023 Nov 13; Vol. 41 (47), pp. 7007-7018. Date of Electronic Publication: 2023 Oct 17.

Evaluation of the Risk of Inflammatory Bowel Disease after the HPV Vaccination in Primary Care in Spain: A Time-Varying Cohort Analysis of Around 390,000 Girls.

Autor: Martín-Merino E; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo 1, Edif. 8, 28022, Madrid, Spain. emartinm@aemps.es., Castillo-Cano B; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo 1, Edif. 8, 28022, Madrid, Spain., Martín-Pérez M; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo 1, Edif. 8, 28022, Madrid, Spain., Llorente-García A; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo 1, Edif. 8, 28022, Madrid, Spain., Montero-Corominas D; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo 1, Edif. 8, 28022, Madrid, Spain.

Publikováno v: Drug safety [Drug Saf] 2021 Apr; Vol. 44 (4), pp. 455-466. Date of Electronic Publication: 2021 Jan 19.

Effect of regulatory interventions on agomelatine use in Spain: A multiple intervention time-series analysis in a nationwide electronic healthcare record database.

Autor: González-Bermejo D; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Castillo-Cano B; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Rodríguez-Pascual A; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., García-Martín MF; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Álvarez-Gutiérrez A; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Montero-Corominas D; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Huerta-Álvarez C; Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2022 Mar; Vol. 31 (3), pp. 294-301. Date of Electronic Publication: 2021 Nov 08.

Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.

Autor: Martín-Merino E; Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain. Electronic address: emartinm@aemps.es., Castillo-Cano B; Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain., Martín-Perez M; Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain., Llorente-García A; Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain., Montero-Corominas D; Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain.

Publikováno v: Vaccine [Vaccine] 2021 Jul 13; Vol. 39 (31), pp. 4306-4313. Date of Electronic Publication: 2021 Jun 24.